Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The B7-1 Study
NCT02327403Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Oct 2015
- Primary completion
- Sep 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belatacept in proteinuria, sponsored by Brigham and Women's Hospital. Primary endpoint: Change in Proteinuria by 25% at 12 months. Started Oct 2015; status: completed.
02
Drugs
belatacept
03
Conditions
proteinuria
Beyond the preview
Go deeper on NCT02327403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02327403.